Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial/Wuhan University
Despite our small number of cases, the potential of HCQ in the treatment of COVID-19 has been
partially confirmed. Considering that there is no better option at present, it is a promising practice to
apply HCQ to COVID-19 under reasonable management. However, Large-scale clinical and basic
research is still needed to clarify its specific mechanism and to continuously optimize the treatment
plan.
partially confirmed. Considering that there is no better option at present, it is a promising practice to
apply HCQ to COVID-19 under reasonable management. However, Large-scale clinical and basic
research is still needed to clarify its specific mechanism and to continuously optimize the treatment
plan.
Abstract: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ. Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group. Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 32) compared with the control group (54.8%, 17 of 32). Notably, all 4 patients progressed to severe illness that occurred in the control group. However, there were 2 patients with mild adverse reactions in the HCQ treatment group. Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.
https://www.msn.com/en-us/health/medical/tiger-at-nyc-s-bronx-zoo-tests-positive-for-coronavirus/ar-BB12coPu
Tiger at NYC's Bronx Zoo tests positive for coronavirus
A tiger at the Bronx Zoo has tested positive for the new coronavirus, in what is believed to be the first known infection in an animal in the U.S. or a tiger anywher